Releases
RCOR-WS
--
0.00%
--
  • All
  • Financials
  • Insiders
More
Webull provides the latest Renovacor Inc (RCOR-WS) stock and general news. This information may help you make smarter investment decisions.
About RCOR-WS
Renovacor, Inc., formerly Chardan Healthcare Acquisition 2 Corp., is a preclinical-stage gene therapy company. The Company is engaged in developing a pipeline of adeno-associated virus (AAV)-based gene therapies for Bcl2-associated athanogene 3 (BAG3) gene mutation-associated diseases in areas of unmet medical need. It focuses on cardiovascular disease, with a lead program in BAG3 mutation-associated dilated cardiomyopathy. Its lead product candidate, REN-001, is an AAV9-based gene therapy designed to treat BAG3-associated dilated cardiomyopathy (DCM).